S100A10 and Alzheimer disease: In contrast, expression of the A2 marker S100A10 was significantly elevated by PBM treatment in AD animals (Cortex: P = 0.0012; Hippocampus: P < 0.001), suggesting that the PBM enhance the neuroprotective A2 phenotype.